此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

89Zr-KN035 PET Imaging in Patients With Advanced Solid Tumors

2018年12月4日 更新者:Miao Liyan、The First Affiliated Hospital of Soochow University

89Zr-labeled KN035 PET Imaging in Patients With PD-L1positive Advanced Solid Tumors

This is a single arm study by using 89Zr-labeled KN035 (89Zr-KN035) PET imaging to evaluate the biodistribution and target lesion uptake of 89Zr-KN035 in patients with PD-L1 positive advanced solid tumors.

研究概览

地位

未知

详细说明

The overall purpose of the study is to evaluate the biodistribution and target lesion uptake of 89Zr-KN035 in patients with PD-L1 positive advanced solid tumors by using PET imaging. Safety will be observed after 89Zr-KN035 injection, and radiation dosimetry of 89Zr-KN035 will be calculated.

研究类型

介入性

注册 (预期的)

10

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Jiangsu
      • Suzhou、Jiangsu、中国、215006
        • 招聘中
        • The First Affiliated Hospital of Soochow University
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria (main):

  1. Patients voluntarily signed informed consent;
  2. Age 18-75, male or female;
  3. Patients diagnosed with locally advanced or metastatic solid tumors by histopathology or cytology;
  4. Patients with biopsy-proven PD-L1 positive;
  5. ECOG score ≤ 0~1; Life expectancy of at least 3 months;
  6. Women of childbearing age are required to receive serum pregnancy tests, and only those who have a negative pregnancy test for eligible subjects.

Exclusion Criteria(main):

  1. Currently or within the first 28 days before the first dose to participate in another therapeutic clinical trial. If participating in a non-interventional clinical trial, it is not be excluded.
  2. Patients with systemic or locally severe infections (CTCAE ≥ 2);
  3. Patients with allergies or allergies to any component of the imaging agent or antibody;
  4. Patients who cannot undergo PET/CT imaging;
  5. Intolerance of intravenous administration, as well as difficulties in venous blood collection (If having the medical history of fainting during acupuncture, and blood phobia);
  6. Symptomatic congestive heart failure (NYHA class II-IV) or symptomatic or poorly controlled arrhythmia;
  7. Patients have significant QT/QTC interval prolongation during the screening period;
  8. Received anti-tumor therapy (including but not limited to chemotherapy, radiotherapy, biological therapy) within 4 weeks prior to first dose;
  9. Patents have not recovered to CTCAE grade 0 or 1 from the adverse events due to cancer therapeutics administered;
  10. Previously received CD137 agonist or immune checkpoint blocking therapy;
  11. Patients with diabetes who have a fasting blood glucose greater than 10 mmol/L;
  12. HIV antibody positive, active hepatitis B/C, and TB positive;
  13. Patients are regular users (including "recreational use") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol);
  14. Patients with symptomatic ascites, pleural effusion, or hydropericardium;
  15. Pregnant or lactating women, or planning to become pregnant or have children during this trial.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:诊断
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:89Zr-KN035 injection
Single injection of 89Zr labeled KN035 in subjects to observe KN035 affinity in PD-L1 expressed Solid tumors by using PET imaging.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Description of regions of interest (ROI) 89Zr-KN035 by measuring standardized uptake value (SUV) on 89Zr-KN035 PET scans
大体时间:6 months
6 months

次要结果测量

结果测量
措施说明
大体时间
Number of adverse events as assessed by CTCAE v4.03
大体时间:6 months
All adverse events will be assessed by CTCAE v 4.03 and evaluated if treatment-related or not.
6 months
Number of changes in laboratory test results as accessed by CTCAE v4.03
大体时间:6 months
Laboratory tests (blood, urine) will be conducted by time. Significant changes will be assessed by CTCAE v 4.03.
6 months
Number of changes in vital signs as accessed by CTCAE v4.03
大体时间:6 months
Vital signs (heart rate, respiratory rate, blood pressures and body temperature) data will be collected by time. Significant changes will be assessed by CTCAE v4.03.
6 months

其他结果措施

结果测量
措施说明
大体时间
Maximum serum concentration of 89Zr-KN035 (Cmax)
大体时间:6 months
Blood samples will be collected and assessed by timepoints.
6 months
Time to Maximum Concentration of 89Zr-KN035 (Tmax)
大体时间:6 months
Blood samples will be collected and assessed by timepoints.
6 months
Calculation of radiation dosimetry of 89Zr-KN035
大体时间:6 months
6 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:liyan Miao, PhD、The First Affiliated Hospital of Soochow University
  • 首席研究员:Jianan Huang, PhD、The First Affiliated Hospital of Soochow University

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2018年11月12日

初级完成 (预期的)

2019年12月1日

研究完成 (预期的)

2019年12月1日

研究注册日期

首次提交

2018年7月23日

首先提交符合 QC 标准的

2018年8月16日

首次发布 (实际的)

2018年8月20日

研究记录更新

最后更新发布 (实际的)

2018年12月5日

上次提交的符合 QC 标准的更新

2018年12月4日

最后验证

2018年12月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • AMS-2017-007-a

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅